A new tablet formulation of SMA treatment Evrysdi (risdiplam) may give patients more "freedom and independence," a Genentech ...

Japanese drugmaker Chugai (TYO: 4519) has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) ...

The Phase 2 VENTURE-Oral Dosing Trial is a randomized, double-blind, placebo-controlled multicenter study designed to evaluate the safety, tolerability, pharmacokinetics and weight loss efficacy ...

Objective: To compare the 24-hour sustained efficacy and safety of a new tramadol once-daily formulation (tramadol OAD) using Contramid ® controlled-release technology with a marketed twice-daily ...

Objective: Spalt-Liqua® is a newsoft gelatin capsule containing 200mg of totally dissolved ibuprofen as the active ingredient. The primary objective of the study was to assess bioequivalence ...

SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for ...

Fette Compacting is on a successful path and presents itself confidently as a strategic partner for the pharmaceutical and ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

"Our meeting with the FDA yesterday was very productive, and we remain on track for an NDA filing of CTx-1301 in mid-2025. We ...

Chugai Pharma’s Evrysdi tablets 5mg receives Japanese approval to treat spinal muscular atrophy: Saturday, March 29, 2025, 11:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd. announ ...

MCC is extensively utilized in the pharmaceutical industry as a disintegrant and bulking agent for tablet formulations, ...

Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) today announces positive interim results from its randomized, double-blind, placebo-controlled Phase Ib single subcutaneous (SQ) injection study ( ...